Here's Bill Bonner's "4th and Final Prediction"
One of America's most successful entrepreneurs goes public with "4th and Final Prediction." His first three all came true—will this one too?
Click here for details...
Timothy P. Walbert, insider at Horizon Therapeutics Public

Timothy P. Walbert Insider Information

Tim Walbert joined Horizon in June 2008 as president and chief executive officer and has served as chairman of the company’s board of directors since 2010. Before joining Horizon, he served as president, chief executive officer and director of IDM Pharma Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings Inc., or Takeda, in June 2009. Before IDM, Walbert served as executive vice president, commercial operations at NeoPharm Inc., a public biopharmaceutical company. From 2001 to 2005, he served as divisional vice president and general manager, immunology, at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic HUMIRA, and served as divisional vice president, global cardiovascular strategy. From 1998 to 2001, Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America and Canada, at G.D. Searle & Company. From 1991 to 1998, he also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co. Inc. and Wyeth.

Walbert received his Bachelor of Arts in business from Muhlenberg College in Allentown, Pa. He serves as chairman of the board of Exicure Inc. and serves on the board of Aurinia Pharmaceuticals Inc. and the Illinois Biotechnology Innovation Organization (iBIO). He is a member of the National Organization for Rare Disorders (NORD) Advisory Board and serves on the Board of Trustees of Muhlenberg College. He previously served on the boards of directors of Raptor Pharmaceutical Corp., a public biopharmaceutical company, from 2010 to 2014; XOMA Corporation, a public biotechnology company, from 2011 to 2017; and Sucampo Pharmaceuticals Inc., a public biopharmaceutical company, from 2016 to 2018.

What is Timothy P. Walbert's net worth?

The estimated net worth of Timothy P. Walbert is at least $29.81 million as of June 3rd, 2022. Mr. Walbert owns 435,826 shares of Horizon Therapeutics Public stock worth more than $29,814,857 as of August 11th. This net worth evaluation does not reflect any other assets that Mr. Walbert may own. Additionally, Mr. Walbert receives a salary of $5,540,000.00 as CEO at Horizon Therapeutics Public. Learn More about Timothy P. Walbert's net worth.

How old is Timothy P. Walbert?

Mr. Walbert is currently 55 years old. There are 7 older executives and no younger executives at Horizon Therapeutics Public. Learn More on Timothy P. Walbert's age.

What is Timothy P. Walbert's salary?

As the CEO of Horizon Therapeutics Public Limited, Mr. Walbert earned a total compensation package of $21,353,458.00 in 2021. Mr. Walbert earned a salary of $1,186,561.00, stock awards of $15,818,363.00, non-equity compensation of $4,174,963.00, and other compensation of $173,571.00. Learn More on Timothy P. Walbert's salary.

How do I contact Timothy P. Walbert?

The corporate mailing address for Mr. Walbert and other Horizon Therapeutics Public executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE 1ST FLOOR, Dublin L2, D04 C5Y6. Horizon Therapeutics Public can also be reached via phone at (531) 772-2100 and via email at [email protected] Learn More on Timothy P. Walbert's contact information.

Has Timothy P. Walbert been buying or selling shares of Horizon Therapeutics Public?

Timothy P. Walbert has not been actively trading shares of Horizon Therapeutics Public during the past quarter. Most recently, Timothy P. Walbert sold 25,000 shares of the business's stock in a transaction on Friday, June 3rd. The shares were sold at an average price of $92.34, for a transaction totalling $2,308,500.00. Following the completion of the sale, the chief executive officer now directly owns 435,826 shares of the company's stock, valued at $40,244,172.84. Learn More on Timothy P. Walbert's trading history.

Who are Horizon Therapeutics Public's active insiders?

Horizon Therapeutics Public's insider roster includes Brian Beeler (EVP), Daniel Camardo (EVP), Geoffrey Curtis (EVP), William Daniel (Director), Michael Desjardin (EVP), Michael Grey (Director), Paul Hoelscher (CFO), Vikram Karnani (EVP), Jeff Kent (Insider), Irina Konstantinovsky (EVP), Miles Mchugh (SVP), Barry Moze (EVP), Andy Pasternak (EVP), Jeffrey Sherman (EVP), Elizabeth Thompson (EVP), and Timothy Walbert (CEO). Learn More on Horizon Therapeutics Public's active insiders.

Are insiders buying or selling shares of Horizon Therapeutics Public?

During the last twelve months, Horizon Therapeutics Public insiders bought shares 1 times. They purchased a total of 745 shares worth more than $49,669.15. During the last twelve months, insiders at the biopharmaceutical company sold shares 35 times. They sold a total of 1,057,327 shares worth more than $110,655,224.55. The most recent insider tranaction occured on August, 4th when EVP Sean M Clayton bought 745 shares worth more than $49,669.15. Insiders at Horizon Therapeutics Public own 2.5 % of the company. Learn More about insider trades at Horizon Therapeutics Public.

Information on this page was last updated on 8/4/2022.

Timothy P. Walbert Insider Trading History at Horizon Therapeutics Public

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/3/2022Sell25,000$92.34$2,308,500.00435,826View SEC Filing Icon  
5/31/2022Sell25,000$92.48$2,312,000.00435,549View SEC Filing Icon  
5/20/2022Sell25,000$90.00$2,250,000.00460,549View SEC Filing Icon  
5/11/2022Sell17,600$90.00$1,584,000.00460,549View SEC Filing Icon  
5/6/2022Sell7,400$90.86$672,364.00460,549View SEC Filing Icon  
4/22/2022Sell25,000$106.59$2,664,750.00485,549View SEC Filing Icon  
4/8/2022Sell25,000$112.38$2,809,500.00485,549View SEC Filing Icon  
3/30/2022Sell50,000$105.26$5,263,000.00View SEC Filing Icon  
3/25/2022Sell25,000$109.37$2,734,250.00View SEC Filing Icon  
3/11/2022Sell25,000$100.93$2,523,250.00View SEC Filing Icon  
2/11/2022Sell25,000$97.41$2,435,250.00View SEC Filing Icon  
1/31/2022Sell100,000$91.85$9,185,000.00View SEC Filing Icon  
1/28/2022Sell25,000$90.00$2,250,000.00View SEC Filing Icon  
1/14/2022Sell25,000$90.02$2,250,500.00View SEC Filing Icon  
11/30/2021Sell50,000$102.40$5,120,000.00View SEC Filing Icon  
11/1/2021Sell25,000$118.49$2,962,250.00View SEC Filing Icon  
9/30/2021Sell50,000$110.30$5,515,000.00View SEC Filing Icon  
7/30/2021Sell25,000$101.74$2,543,500.00View SEC Filing Icon  
4/30/2021Sell25,000$94.98$2,374,500.00920,710View SEC Filing Icon  
1/22/2021Sell11,323$76.47$865,869.81966,889View SEC Filing Icon  
1/15/2021Sell211,204$77.89$16,450,679.561,076,362View SEC Filing Icon  
8/6/2020Sell110,000$72.54$7,979,400.00View SEC Filing Icon  
2/21/2020Sell93,864$35.23$3,306,828.72963,064View SEC Filing Icon  
1/6/2020Sell84,886$35.57$3,019,395.02987,991View SEC Filing Icon  
10/15/2019Sell320,174$28.02$8,971,275.48892,483View SEC Filing Icon  
8/30/2019Sell2,500$28.00$70,000.00785,296View SEC Filing Icon  
8/22/2019Sell58,820$28.00$1,646,960.00View SEC Filing Icon  
8/21/2019Sell56,836$28.00$1,591,408.00View SEC Filing Icon  
11/14/2018Sell408,347$21.54$8,795,794.38650,404View SEC Filing Icon  
6/1/2018Sell83,353$16.17$1,347,818.01View SEC Filing Icon  
11/19/2014Sell150,000$12.05$1,807,500.00View SEC Filing Icon  
See Full Table

Timothy P. Walbert Buying and Selling Activity at Horizon Therapeutics Public

This chart shows Timothy P Walbert's buying and selling at Horizon Therapeutics Public by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Horizon Therapeutics Public Company Overview

Horizon Therapeutics Public logo
Horizon Therapeutics Public Limited Company, a biotechnology company, focuses on the discovery, development, and commercialization of medicines that address critical needs for people impacted by rare, autoimmune, and severe inflammatory diseases. The company operates in two segments, Orphan and Inflammation. Its portfolio comprises 12 medicines in the areas of rare diseases, gout, ophthalmology, and inflammation. It markets TEPEZZA (teprotumumab-trbw) for intravenous infusion; KRYSTEXXA (pegloticase injection) for intravenous infusion; RAVICTI (glycerol phenylbutyrate) oral liquid; PROCYSBI (cysteamine bitartrate) delayed-release capsules and granules for oral use; ACTIMMUNE (interferon gamma-1b) injection for subcutaneous use; BUPHENYL (sodium phenylbutyrate) tablets and powder for oral use; QUINSAIR (levofloxacin) solution for inhalation; and UPLIZNA (inebilizumab-cdon) injection for intravenous use. The company also markets PENNSAID (diclofenac sodium topical solution) for topical use; DUEXIS (ibuprofen/famotidine) tablets for oral use; RAYOS (prednisone) delayed-release tablets for oral use; and VIMOVO (naproxen/esomeprazole magnesium) delayed-release tablets for oral use. It has collaboration agreements with HemoShear Therapeutics, LLC.; Alpine Immune Sciences, Inc.; Halozyme Therapeutics, Inc.; and Arrowhead Pharmaceuticals, Inc. The company was formerly known as Horizon Pharma Public Limited Company and changed its name to Horizon Therapeutics Public Limited Company in May 2019. Horizon Therapeutics Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland with additional offices in Deerfield, Illinois; Chicago, Illinois; Lake Forest, Illinois; South San Francisco, California; Washington, D.C.; Gaithersburg, Maryland; Rockville, Maryland; and Mannheim, Germany.
Read More

Today's Range

Now: $68.41
Low: $67.14
High: $69.03

50 Day Range

MA: $81.65
Low: $66.96
High: $92.39

2 Week Range

Now: $68.41
Low: $60.76
High: $120.54


2,751,342 shs

Average Volume

2,067,057 shs

Market Capitalization

$15.76 billion

P/E Ratio


Dividend Yield



Here's Bill Bonner's "4th and Final Prediction"
One of America's most successful entrepreneurs goes public with "4th and Final Prediction." His first three all came true—will this one too?
Click here for details...